Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
1.
Chinese Journal of Hematology ; (12): 514-518, 2009.
Article de Chinois | WPRIM | ID: wpr-283932

RÉSUMÉ

<p><b>OBJECTIVE</b>To explore the feasibility and safety of conditioning regimen containing fludarabine (Flud) for haploidentical hematopoietic stem cell transplantation (HSCT).</p><p><b>METHODS</b>Preparative regimen containing Flud 40 mgxm(-2)xd(-1) on day -7 to -3 in place of cyclophosphamide (CTX) for haploidentical HSCT was given to 35 patients with hematologic malignancies (4 standard risk, 16 high risk, 15 relapse with no remission). All donors received rhG-CSF followed by HSC harvest. One patient received peripheral blood HSCT (PBSCT), one bone marrow transplantation (BMT), and the others BM combination with PBSCT. The regimen-associated side effect, engraftment, incidence of graft-versus-host disease (GVHD) and disease-free survival (DFS) probabilities were observed.</p><p><b>RESULTS</b>All patients achieved sustained, full donor-type engraftment. Thirty-four patients obtained primary durable engraftment, and 1 who rejected graft from his mother obtained successful durable engraftment after the second graft from his father. The cumulative incidence of grade III-IV acute GVHD and chronic GVHD was 12.1% and 31.7%, respectively. With a follow-up duration of 8-25 months, 6 patients were dead, in which 3 died of relapse, 2 of acute GVHD, 1 of fungal infection, none died of regimen-associated side effect. The other 29 patients remained alive and DFS probability was 79.7%.</p><p><b>CONCLUSION</b>Flud based conditioning regimens for haploidentical HSCT is safe and feasible, which reduces regimen-associated side effect, with no increasing the rate of relapse and infection, and decreases the incidence of aGVHD.</p>


Sujet(s)
Adolescent , Adulte , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Cyclophosphamide , Études de faisabilité , Maladie du greffon contre l'hôte , Transplantation de cellules souches hématopoïétiques , Conditionnement pour greffe , Méthodes , Transplantation homologue , Vidarabine , Utilisations thérapeutiques
2.
Article de Chinois | WPRIM | ID: wpr-234186

RÉSUMÉ

<p><b>OBJECTIVE</b>To survey the married couples at reproductive age for contraceptive knowledge in 5 Chinese cities.</p><p><b>METHODS</b>The data derived from a questionnaire-based research conducted in 2002 on family planning among married couples in 5 Chinese cities were statistically analyzed.</p><p><b>RESULTS</b>The total rate of good contraceptive knowledge was 70.10% in the couples. Among all the contraceptive measures, condom use was the most familiar one. The understanding of contraceptive knowledge in couples working in official departments and educational institutes was better than that among the couples working in common enterprises, affected by such factors as gender, geographic regions, educational background and willingness of child-bearing.</p><p><b>CONCLUSION</b>The married couples in the Chinese cities have generally good understanding of contraceptive knowledge, which can be affected by different factors among different populations.</p>


Sujet(s)
Adulte , Femelle , Humains , Mâle , Chine , Villes , Contraception , Comportement contraceptif , Modèles logistiques , Mariage , Enquêtes et questionnaires , Population urbaine
3.
Chinese Journal of Pediatrics ; (12): 599-602, 2005.
Article de Chinois | WPRIM | ID: wpr-312111

RÉSUMÉ

<p><b>OBJECTIVE</b>Allogeneic marrow transplantation is a curative therapy for thalassemia, but no more than 30% of patients have HLA-indentical sibling marrow donor. The selection of alternative donors of unrelative marrow and the study on the probability of treating thalassemia major with unrelated donor bone marrow transplantation are of importance.</p><p><b>METHODS</b>Nine children with thalassemia were included in the study, and their gene mutational type were homozygote of thalassemia and double heterozygote, respectively. All of them were finally diagnosed of thalassemia major, and treated with unrelated donor bone marrow transplantation. To high-resolution HLA typing, two patients were matched, five had one unmatched isoform and two had two unmatched isoforms. The erythrocyte blood type was not matched in six patients. The preparative regimen included busulfan (oral use, 16 mg/kg, divided for 4 days), cyclophosphamide (intravenous use, 200 mg/kg, divided for 4 days), antithymocyte immunoglobulin (intravenous use, 30 mg/kg, divided for 3 days), and fludarabine (intravenous use, 125 mg/m(2), divided for 3 days). Ciclosporin A and methotrexate were used for graft-versus-host disease (GVHD) prophylaxis.</p><p><b>RESULTS</b>All patients had allergen reactions. One had hypotension. Five patients experienced I degrees approximately III degrees acute GVHD in the skin, while one had II degrees acute GVHD in liver. One patient had III degrees GVHD of intestines and gradually developed chronic GVHD in the skin, lungs and brain. One patient died of pulmonary hemorrhage. The duration when peripheral blood neutrophil count exceeded 0.5 x 10(9)/L was 12 - 26 days. The recovery time of WBC was as long as 23 - 110 days. Thrombocytes exceeded 50 x 10(9) within 61 approximately 142 days. The time when hemoglobin reached 100 g/L varied from 23 to 116 days. The last blood transfusion was on 13 - 62 days. Eight patients were fully grafted, while one was not grafted. During the 6 - 24 months of follow-up, seven patients' genotype of thalassemia major became normal. The erythrocyte blood type of five patients also changed into the same as that of donor. The hemoglobin was kept over 110 g/L without blood transfusion.</p><p><b>CONCLUSION</b>The transplantation of unrelated donor bone marrow for thalassemia major was successful. Unrelated donor bone marrow transplantation could cure thalassemia major, which expanded the marrow donor source for the transplantation of thalassemia major.</p>


Sujet(s)
Enfant , Enfant d'âge préscolaire , Femelle , Humains , Nourrisson , Mâle , Système ABO de groupes sanguins , Transplantation de moelle osseuse , Survie sans rechute , Études de suivi , Rejet du greffon , Survie du greffon , Test d'histocompatibilité , Tolérance à la transplantation , Transplantation homologue , Résultat thérapeutique , bêta-Thalassémie , Diagnostic , Thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE